Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy.

Dr. Neil Bressler has been a member of the Wilmer Eye Institute's faculty since 1988 and is the inaugural James P. Gills Professor of Ophthalmology. He specializes in retinal diseases, with special interests in diabetic retinopathy and macular degeneration. Dr. Bressler's main research interests have been collaborative efforts in clinical trials of common retinal diseases, including age-related macular degeneration and diabetic retinopathy, having chaired several NIH-sponsored and industry-sponsored multicenter randomized clinical trials and authored almost 300 peer-reviewed publications. He is a past chair of the NIH-sponsored Diabetic Retinopathy Clinical Research Network, and was responsible for guidelines, policies, protocol development as well as implementation, and to facilitate Network operations in a way that maintains academic integrity and optimal clinical trial performance. He also has chaired the National Eye Institutes Data and Safety Monitoring Committee for intramural clinical trials and the FDA Ophthalmic Devices Panel. Dr. Bressler is currently editor-in-chief of JAMA Ophthalmology. Dr. Bressler is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal.

Dr. Susan Bressler is the Julia G. Levy, Ph.D. Professor of Ophthalmology at the Wilmer Eye Institute. She is an ophthalmologist and has subspecialty training in medical retinal disorders, vitreoretinal disease, and retinal surgery. Her main research interest has been collaborative efforts in clinical trials - serving as principal investigator of an image reading center that has served as a central unit for many clinical trials and epidemiologic investigations, as Vice Chair of the Diabetic Retinopathy Clinical Research Network and as principal investigator of a participating clinical center in several major clinical trials. Most studies have specific emphasis on the treatment of both non-neovascular and neovascular age-related macular degeneration and all aspects of diabetic retinopathy. Dr. Bressler has a large national and international referral practice. In addition, she has published 223 peer reviewed articles and 55 book chapters. Editorial Board positions have included American Journal of Ophthalmology, Survey of Ophthalmology, Retina, EyeNet Magazine, Health After 50: The Johns Hopkins Medical Letter and the Wilmer Retina Update. Dr. Bressler is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. Her top areas of expertise are Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, and Vitrectomy.

Yannis M. Paulus, M.D., F.A.C.S., is the Jonas Fridenwald Professor in Ophthalmology, an associate professor in the Johns Hopkins University Department of Ophthalmology and Department of Biomedical Engineering, and a vitreoretinal surgeon at the Wilmer Eye Institute, Johns Hopkins Medicine’s East Baltimore and Columbia locations. Dr. Paulus served as a surgical retina specialist and director of a research laboratory at the University of Michigan Kellogg Eye Center for almost 10 years, where he developed novel imaging systems, lasers and long-lasting therapies and nanotechnologies to allow physicians to determine cellular markers of disease, enabling early diagnosis, improved treatment monitoring and more individualized, personalized precision medicine tailored to each patient’s needs. After earning his bachelor’s degree in chemistry and physics from Harvard University and his medical degree at Stanford University School of Medicine, Dr. Paulus completed an internship at the Sloan-Kettering Cancer Center, a residency in ophthalmology at the Stanford University School of Medicine Byers Eye Institute, and a surgical and medical retina fellowship at Wilmer Eye Institute, Johns Hopkins Medicine. CVhttps://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Paulus_CV%2021225.pdf. Dr. Paulus is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Diabetic Retinopathy, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Vitrectomy, and Cataract Removal.

James T. Handa, M.D., is Chief of the Retina Division and the Robert Bond Welch, M.D., Professor of Ophthalmology at the Wilmer Eye Institute. He specializes in medical and surgical management of complex vitreoretinal diseases such as age-related macular degeneration, diabetic retinopathy, retinal detachment, retinopathy of prematurity and other pediatric retinal diseases. He also has expertise in intraocular oncology and manages patients with choroidal melanomas and metastatic tumors of the eye. Not only is he a highly skilled surgeon and clinician, but he also devotes significant effort to research related to the early causes of age-related macular degeneration using molecular pathological approaches to understand how the eye transforms from normal aging to early disease. He has been funded by the National Eye Institute for the last 19 years, and he currently holds two R01 awards for his work in AMD. He has also been funded by the Thome Foundation, Research to Prevent Blindness, Fight for Sight and the American Health Assistance Foundation. His other research focuses on surgical innovation using an integrated robotic surgical system. Dr. Handa is currently the Wilmer Eye Institute’s implanting surgeon for the Argus II retinal chip implant, which was recently approved by the FDA after Dr. Handa participated in the clinical trial leading to its approval. Dr. Handa is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Melanoma of the Eye, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Metastatic Uveal Melanoma, and Vitrectomy.

Allen Hu is an Ophthalmologist in Cumberland, Maryland. Dr. Hu is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Geographic Atrophy, Diabetic Retinopathy, and Vitrectomy.

Emily Chew is an Ophthalmologist in Bethesda, Maryland. Dr. Chew is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. Her top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Diabetic Retinopathy, and Cataract Removal.

Catherine Cukras is an Ophthalmologist in Bethesda, Maryland. Dr. Cukras is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. Her top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Geographic Atrophy, and Retinopathy Pigmentary Mental Retardation.

Tiarnan Keenan is an Ophthalmologist in Bethesda, Maryland. Dr. Keenan is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Geographic Atrophy, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Von Hippel-Lindau (VHL) Syndrome, and Cataract Removal.

Michael Elman is an Ophthalmologist in Baltimore, Maryland. Dr. Elman is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, Retinal Vein Occlusion, and Vitrectomy. Dr. Elman is currently accepting new patients.

Akrit Sodhi, M.D, Ph.D., is an Associate Professor of Ophthalmology at the Wilmer Eye Institute and holds the Branna and Irving Sisenwein Professorship in Ophthalmology. Dr. Sodhi specializes in the medical and surgical management of complex vitreoretinal diseases. Dr. Sodhi was trained at the University of California at Los Angeles (UCLA), the University of California at Davis, and the National Institutes of Health. After obtaining his M.D. and Ph.D., he interned at Sinai Hospital in Baltimore and completed his Ophthalmology Residency training at the Wilmer Eye Institute at Johns Hopkins in 2008. He then pursued a fellowship in vitreoretinal surgery at Wilmer where he also served as the Assistant Chief of Service (Chief Resident). Dr. Sodhi joined the faculty of the Retina Division at Wilmer in 2010. His research interests, currently sponsored by grants from the National Eye Institute, include the examination of the role of hypoxia inducible factor (HIF) and HIF-regulated genes in ocular diseases, including diabetic eye disease, age-related macular degeneration, sickle cell retinopathy, retinal vein occlusions, and uveal melanoma. Dr. Sodhi's lab has identified novel therapeutic targets for the treatment of these vision-threatening diseases. Dr. Sodhi is rated as a Distinguished provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Retinal Vein Occlusion, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, and Late-Onset Retinal Degeneration.

Sharon D. Solomon, M.D., is the Katharine M. Graham Professor of Ophthalmology at the Wilmer Eye Institute. A retina specialist and ophthalmologist, Dr. Solomon's clinical expertise includes medical and surgical treatment of age-related macular degeneration, diabetic retinopathy, epiretinal membranes, macular holes, and retinal tears and detachment. Dr. Solomon has a large national and international referral practice at Wilmer. Dr. Solomon has served as principal investigator at Wilmer on a number of NIH-sponsored clinical trials. She has numerous publications from her clinical trials involvement. Dr. Solomon received her bachelor's degree in biochemistry from Harvard University and her medical degree from the University of California, San Francisco. After her internship at Stanford, she returned to UCSF for her residency in ophthalmology. Dr. Solomon completed her surgical retina fellowship at the Wilmer Eye Institute prior to joining the faculty. Dr. Solomon is a member of the prestigious Miller-Coulson Academy of Clinical Excellence at Johns Hopkins. Dr. Solomon is rated as a Distinguished provider by MediFind in the treatment of Late-Onset Retinal Degeneration. Her top areas of expertise are Retinal Vein Occlusion, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Gyrate Atrophy of the Choroid and Retina, and Vitrectomy.

Elia J. Duh, M.D., is the G. Edward and G. Britton Durell Professor of Ophthalmology at the Wilmer Eye Institute. He has a joint appointment in the Department of Chemical and Biomolecular Engineering, The Whiting School of Engineering. He specializes in diseases of the retina, including diabetic retinopathy and age-related macular degeneration. In addition to his clinical practice, Dr. Duh actively researches the molecular mechanisms underlying diabetic retinopathy and macular degeneration, particularly the process of ocular neovascularization and excessive retinal vascular permeability. His research has helped determine the role of the major antioxidant regulator, Nrf2, in retinal diseases, and also connected Nrf2 to lifespan. His work has also provided insights into the involvement of the eye in COVID-19. Dr. Duh’s interest in developing new treatments for retinal diseases includes nanomedicine approaches for targeted drug delivery to the eye. Dr. Duh graduated summa cum laude from Yale University and obtained his medical degree from Harvard Medical School. He completed his ophthalmology residency and medical retina fellowship at the Wilmer Eye Institute. He was elected to the American Society of Clinical Investigation in 2016. Dr. Duh is rated as a Distinguished provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Diabetic Retinopathy, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Retinal Vein Occlusion, and Vitrectomy.

Dr. Sastry is a fellowship trained ophthalmologist specializing in retina, macula, vitreous diseases and surgery. He has been selected as one of America's Top Ophthalmologists and one of Washingtonian Magazines Top Doctors 2010. He has a special interest in treatment of macular degeneration, diabetic retinopathy and has performed several thousand retina procedures. Dr. Sastry received his MD degree in India in 1989 and M.P.H. degree from Harvard University, Boston in 1990. He is a member of the American Academy of Ophthalmology. Dr. Sastry has presented research at national and international meetings and has published numerous articles on ophthalmology and the prevention of eye disease. To learn more about Dr.Sastry, visit BethesdaRetina.com. Dr. Sastry is rated as a Distinguished provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Kallikrein Hypertension, and Glaucoma.

Rohit Lakhanpal is an Ophthalmologist in Baltimore, Maryland. Dr. Lakhanpal is rated as a Distinguished provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Late-Onset Retinal Degeneration, Diabetic Retinopathy, Age-Related Macular Degeneration (ARMD), Retinal Artery Occlusion, and Vitrectomy. Dr. Lakhanpal is currently accepting new patients.

Jordan Heffez is an Ophthalmologist in Bethesda, Maryland. Dr. Heffez is rated as a Distinguished provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Late-Onset Retinal Degeneration, X-Linked Retinal Dysplasia, X-Linked Juvenile Retinoschisis, Age-Related Macular Degeneration (ARMD), and Vitrectomy.

David Parver is an Ophthalmologist in Bethesda, Maryland. Dr. Parver is rated as a Distinguished provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Neuroretinitis, and Hyphema.

Adam Wenick is an Ophthalmologist in Hagerstown, Maryland. Dr. Wenick is rated as a Distinguished provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Retinal Vein Occlusion, Retinal Detachment, and Vitrectomy. Dr. Wenick is currently accepting new patients.

Timothy D. Polk, MD, specializes in comprehensive ophthalmology. He is affiliated with UPMC Memorial. Dr. Polk completed his fellowships at the University of Iowa Hospitals and Clinics and Bascom Palmer Eye Institute, residency at Greater Baltimore Medical Center and medical degree at the University of Virginia School of Medicine. Dr. Polk is rated as a Distinguished provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Retinal Artery Occlusion, Retinal Vein Occlusion, and Vitrectomy.

Douglas A. Jabs, M.D., M.B.A. is an internationally-recognized expert in the evaluation and management of patients with uveitis and related immune-mediated ocular disorders, particularly on the use of immunosuppression to treat severe ocular inflammatory diseases. Founder of the Division of Ocular Immunology and Uveitis at Wilmer, he now is the Director of the Center for Clinical Trials and Evidence Synthesis at the Johns Hopkins University Bloomberg School of Public Health. Dr. Jabs is rated as an Advanced provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Uveitis, CMV Retinitis, Scleritis, Cataract Removal, and Trabeculectomy.